Who are AMG 162 - Prolia's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Denosumab Prefilled Syringe [Prolia], Placebo to Denosumab, Denosumab De-escalation, Romosozumab and Denosumab Cycle Therapy, BONCRESA, Xgeva®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amg-162-prolia.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AMG 162 - Prolia — Competitive Intelligence Brief

AMG 162 - Prolia (AMG 162 - Prolia) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RANKL inhibitor. Area: Bone disorders.

phase 2 RANKL inhibitor RANKL Bone disorders Small molecule Live · refreshed every 30 min

Target snapshot

AMG 162 - Prolia (AMG 162 - Prolia) — Amgen. AMG 162, also known as Prolia, is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AMG 162 - Prolia TARGET	AMG 162 - Prolia	Amgen	phase 2	RANKL inhibitor	RANKL
Denosumab Prefilled Syringe [Prolia]	Denosumab Prefilled Syringe [Prolia]	Seoul National University Bundang Hospital	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Placebo to Denosumab	Placebo to Denosumab	Amgen	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Denosumab De-escalation	Denosumab De-escalation	National Taiwan University Hospital	marketed	RANKL inhibitor monoclonal antibody de-escalation strategy	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Romosozumab and Denosumab Cycle Therapy	Romosozumab and Denosumab Cycle Therapy	National Taiwan University Hospital	marketed	Bone-forming agent and antiresorptive agent combination therapy	Sclerostin (romosozumab); RANKL (denosumab)
BONCRESA	DENOSUMAB-MOBZ	AMNEAL PHARMS LLC	marketed	RANK Ligand Inhibitor [EPC]	RANKL
Xgeva®	Xgeva®	Jiangsu Hansoh Pharmaceutical Co., Ltd.	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RANKL inhibitor class)

Amgen · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMG 162 - Prolia — Competitive Intelligence Brief. https://druglandscape.com/ci/amg-162-prolia. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab